In recent years, osimertinib shows superior overall survival (OS) and progression free survival (PFS) compared with the first-generation EGFR-TKIs (gefitinib or erlotinib) as first-line treatment in NSCLC patients with EGFR mutations [10]. Here, EGFR is linked to non-small cell lung carcinoma.